blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3554551

EP3554551 - CYCLODEXTRIN CONJUGATES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  16.04.2021
Database last updated on 31.08.2024
FormerRequest for examination was made
Status updated on  20.09.2019
FormerThe international publication has been made
Status updated on  23.06.2018
Formerunknown
Status updated on  09.02.2018
Most recent event   Tooltip07.02.2024New entry: Decision on request for further processing 
Applicant(s)For all designated states
University College Cork-National University of Ireland, Cork
College Road
Cork / IE
[2019/43]
Inventor(s)01 / DARCY, Raphael
58 Clonard Drive
Dublin D16 Y3E3 / IE
02 / O'DRISCOLL, Caitriona
1 The View
Lover's Walk
Montenotte
Cork T23 F9R3 / IE
03 / MALHOTRA, Meenakshi
331 Curtner Avenue
Apt. L
Palo Alto, CA 94306 / US
 [2019/43]
Representative(s)Purdylucey Intellectual Property
6-7 Harcourt Terrace
D02 FH73 Dublin 2 / IE
[2019/43]
Application number, filing date17835816.414.12.2017
[2019/43]
WO2017EP82941
Priority number, dateEP2016020418414.12.2016         Original published format: EP 16204184
[2019/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018109138
Date:21.06.2018
Language:EN
[2018/25]
Type: A1 Application with search report 
No.:EP3554551
Date:23.10.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 21.06.2018 takes the place of the publication of the European patent application.
[2019/43]
Search report(s)International search report - published on:EP21.06.2018
ClassificationIPC:A61K47/61, A61K47/62, A61K47/69
[2019/43]
CPC:
A61K47/61 (EP,US); A61K47/6951 (EP,US); A61K31/7105 (US);
A61K47/62 (EP,US); A61K47/6929 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/43]
TitleGerman:CYCLODEXTRINKONJUGATE[2019/43]
English:CYCLODEXTRIN CONJUGATES[2019/43]
French:CONJUGUÉS DE CYCLODEXTRINE[2019/43]
Entry into regional phase08.07.2019National basic fee paid 
08.07.2019Designation fee(s) paid 
08.07.2019Examination fee paid 
Examination procedure08.07.2019Examination requested  [2019/43]
08.07.2019Date on which the examining division has become responsible
18.03.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
13.05.2020Amendment by applicant (claims and/or description)
16.04.2021Despatch of a communication from the examining division (Time limit: M06)
26.10.2021Reply to a communication from the examining division
15.09.2023Despatch of a communication from the examining division (Time limit: M04)
29.01.2024Reply to a communication from the examining division
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
29.01.2024Request for further processing filed
29.01.2024Full payment received (date of receipt of payment)
Request granted
06.02.2024Decision despatched
13.05.2020Request for further processing filed
13.05.2020Full payment received (date of receipt of payment)
Request granted
25.05.2020Decision despatched
Fees paidRenewal fee
20.12.2019Renewal fee patent year 03
22.12.2020Renewal fee patent year 04
22.12.2021Renewal fee patent year 05
22.12.2022Renewal fee patent year 06
29.12.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[AD]WO2010000869  (UNIV DUBLIN [IE], et al) [AD] 1 * examples 3-4; claims 1-11, 16, 21-23 *;
 [A]WO2014194250  (UNIV CINCINNATI [US]) [A] 1* paragraphs [00120] - [00126] *;
 [XI]WO2015107115  (BASF SE [DE]) [X] 1-4,7,8,22-36 * page 17, paragraph last - page 19, paragraph 3rd; figures 1-7 * * page 13, lines 23-27 * [I] 5,6,9-13;
 [A]  - GOODING MATT ET AL, "Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells:In vitroanalysis", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, (20150219), vol. 71, doi:10.1016/J.EJPS.2015.02.007, ISSN 0928-0987, pages 80 - 92, XP029146347 [A] 1 * abstract * * page 81, column l, paragraphs 1-3 *

DOI:   http://dx.doi.org/10.1016/j.ejps.2015.02.007
by applicantEP1287039
 US2006148756
 US7786095
 EP2303929
 US2011124103
    - FITZGERALD KA.; MALHOTRA M.; GOODING M.; SALLAS F.; EVANS JC.; DARCY R.; O' DRISCOLL CM., "A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor", Int. J., Pharm., (20160000), vol. 499, pages 131 - 145
    - FITZGERALD KA.; GUO G.; TIERNEY EG.; CURTIN CM.; MALHOTRA M.; DARCY R.; O' BRIEN FJ.; O'DRISCOLL CM., "The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics", Biomaterials, (20150000), vol. 66, pages 53 - 66
    - EVANS JC.; MCCARTHY J.; TORRES-FUENTES C.; CRYAN JF.; OGIER J.; DARCY R.; WATSON RW.; O'DRISCOLL CM., "Cyclodextrin mediated delivery of NF- B and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro", Gene Therapy, (20150000), vol. 22, no. 10, pages 802 - 810
    - GOODING M.; MALHOTRA M.; MCCARTHY DJ.; GODINHO BMDC.; CRYAN JF.; DARCY R.; O'DRISCOLL CM., "Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in-vitro analysis", Eur J Pharm., Sci., (20150000), vol. 71, pages 80 - 92
    - GODINHO BMDC; OGIER JR; QUINLAN A; DARCY R; GRIFFIN BT; CRYAN JF; O'DRISCOLL CM, "PEGylated cyclodextrins as Novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability", Int. J. Pharm., (20140000), vol. 473, pages 105 - 112
    - O'MAHONY AM.; CRONIN MF.; MCMAHON A.; EVANS JC.; DALY K.; DARCY R.; O'DRISCOLL CM, "Biophysical and Structural Characterisation of Nucleic Acid Complexes with Modified Cyclodextrins Using Circular Dichroism", J. Pharm., Sci., (20140000), vol. 103, pages 1346 - 1355
    - HIBBITTS A; O'MAHONY AM; FORDE E; NOLAN L; OGIER J; DESGRANGES S; DARCY R; MACLOUGHLIN R; O'DRISCOLL CM; CRYAN SA, "Early-Stage Development of Novel Cyclodextrin-siRNA Nanocomplexes Allows for Successful Postnebulization Transfection of Bronchial Epithelial Cells", Journal of Aerosol Medicine & Pulmonary Drug Delivery, (20140000), vol. 27, no. 6, pages 466 - 477
    - GODINHO BMDC.; MCCARTHY DJ.; TORRES-FUENTES C.; BELTRAN CJ.; MCCARTHY J.; QUINLAN A.; OGIER JR.; DARCY R.; O'DRISCOLL CM.; CRYAN J, "Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system", Biomaterials, (20140000), vol. 35, doi:doi:10.1016/j.biomaterials.2013.09.068, pages 489 - 499, XP028762486

DOI:   http://dx.doi.org/10.1016/j.biomaterials.2013.09.068
    - O'NEILL M.; O'MAHONY A.; BYRNE C.; DARCY R.; O'DRISCOLL CM., "Gastrointestinal gene delivery by Modified Cyclodextrins - in vitro identification and quantification of extracellular barriers", Int J Pharmaceutics, (20130000), vol. 456, pages 390 - 399
    - O'MAHONY AM; OGIER J; DARCY R; CRYAN JF; O'DRISCOLL CM, "Cationic and PEGylated amphiphilic Cyclodextrins: Co-formulation opportunities for neuronal siRNA delivery", PLoS ONE, (20130000), vol. 8, no. 6, page e66413
    - MCCARTHY J.; O'NEILL MJ.; BOUREE L.; WALSH DP.; QUINLAN A.; HURLEY G.; OGIER J.; SHANAHAN F.; MELGAR S.; DARCY R, "Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system", J. Cont., Rel., (20130000), vol. 168, doi:doi:10.1016/j.jconrel.2013.03.004, pages 28 - 34, XP028543682

DOI:   http://dx.doi.org/10.1016/j.jconrel.2013.03.004
    - VILLARI, V.; MAZZAGLIA, A.; DARCY, R.; O'DRISCOLL, CM; MICALI, N, "Nanostructures of cationic amphiphilic cyclodextrin complexes with DNA", Biomacromolecules, (20130000), vol. 14, pages 811 - 817
    - GODINHO BMDC; OGIER JR; DARCY R; O'DRISCOLL CM; CRYAN JF, "Self-assembling Modified Beta-Cyclodextrin Nanoparticles as Neuronal siRNA Delivery Vectors: Focus on Huntington's Disease", Molecular Pharmaceutics, (20130000), vol. 10, pages 640 - 649
    - O'MAHONY, AM; DESGRANGES S.; OGIER JR.; QUINLAN A.; DEVOCELLE M.; DARCY, R.; CRYAN, JF; O'DRISCOLL, CM, "In vitro investigations of the efficacy of Cyclodextrin-siRNA complexes modified with Lipid-PEG-Octaarginine: Towards A Formulation Strategy for Effective Neuronal siRNA Delivery", Pharm. Res., (20130000), vol. 30, no. 4, pages 1086 - 1098
    - O'MAHONY, AM; DOYLE, D; DARCY, R; CRYAN, JF; O'DRISCOLL, CM, "Characterisation of cationic amphiphilic cyclodextrins for neuronal delivery of siRNA: effect of reversing primary and secondary face modifications", Eur. J. Pharm., Sci., (20120000), vol. 47, pages 896 - 903
    - O'MAHONY AM; GODINHO BMDC; OGIER J; DEVOCELLE M; DARCY R; CRYAN JF; O'DRISCOLL CM, "Click-modified cyclodextrins as non-viral vectors for neuronal siRNA delivery", ACS Chemical Neuroscience, (20120000), vol. 10, no. 3, pages 744 - 52
    - GUO J; OGIER J; DESGRANGES S; DARCY R; O'DRISCOLL CM, "Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice", Biomaterials, (20120000), vol. 33, pages 7775 - 7784
    - O'MAHONY AM; OGIER J; DESGRANGES S; CRYAN JF; DARCY R; O'DRISCOLL CM, "A click chemistry route to 2-functionalised PEGylated and cationic Beta-cyclodextrins: co-formulation opportunities for siRNA delivery", Organic & Biomolecular Chemistry, (20120000), vol. 10, pages 4954 - 496
    - MCMAHON A; O'NEILL MJ; GOMEZ E; DONOHUE R; FORDE D; DARCY R; O'DRISCOLL CM, "Targeted gene delivery to hepatocytes with galactosylated amphiphilic cyclodextrins", J. Pharmacy and Pharmacology, (20120000), vol. 54, pages 1063 - 1073
    - O'NEILL MJ; GUO J; BYRNE C; DARCY R; O'DRISCOLL CM, "Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells", Int. J. Pharmaceutics, (20110000), vol. 413, doi:doi:10.1016/j.ijpharm.2011.04.021, pages 174 - 183, XP028374009

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2011.04.021
    - MCMAHON A; GOMEZ E; DONOHUE R; FORDE D; DARCY R; O'DRISCOLL CM, "Cyclodextrin gene vectors: cell trafficking and the influence of lipophilic chain length", J. Drug Del. Sci. Tech., (20080000), vol. 18, no. 5, pages 303 - 307
    - CRYAN SA; HOLOHAN A; DONOHUE R; DARCY R; O'DRISCOLL CM, "Cell transfection with polycationic cyclodextrin vectors", Eur. J. Pharm. Sci, (20040000), vol. 21, doi:doi:10.1016/j.ejps.2004.01.001, pages 625 - 633, XP008047083

DOI:   http://dx.doi.org/10.1016/j.ejps.2004.01.001
    - CRYAN SA; DONOHUE R; RAVOO BJ; DARCY R; O'DRISCOLL CM, "Cationic cyclodextrin amphiphiles as gene delivery vectors.", J. Drug Del. Sci. Tech., (20040000), vol. 14, no. 1, pages 57 - 62
    - O'MAHONY AM; O'NEILL MJ; GODINHO BMDC; DARCY, R; CRYAN JF; O'DRISCOLL CM, "Cyclodextrins for Non-Viral Gene and siRNA Delivery", Pharmaceutical Nanotechnology, (20130000), vol. 1, pages 6 - 14
    - O'DRISCOLL CM; DARCY R, "Cyclodextrin constructs for delivery of genotherapeutic agents", World Market Series, Business Briefing, PharmaTech, (20020000), pages 1 - 5
    - O'MAHONY, AM; DESGRANGES S; OGIER JR; QUINLAN A; DEVOCELLE M; DARCY R; CRYAN JF; O'DRISCOLL CM, "In vitro investigations of the efficacy of Cyclodextrin-siRNA complexes modified with Lipid-PEG-Octaarginine: Towards a Formulation Strategy for Effective Neuronal siRNA Delivery", Pharm. Res., (20130000), vol. 30, no. 4, pages 1086 - 1098
    - BILENSOY et al., Expert Opin Drug Deliv, (20091100), vol. 6, no. 11
    - ALEJANDRO DAZ-MOSCOSO et al., "Polycationic Amphiphilic Cyclodextrins for Gene Delivery: Synthesis and Effect of Structural Modifications on Plasmid DNA Complex Stability, Cytotoxicity, and Gene ExpressionChem", Eur. J., (20090000), vol. 15, doi:doi:10.1002/chem.200901149, pages 12871 - 12888, XP055014224

DOI:   http://dx.doi.org/10.1002/chem.200901149
    - Microbiol Mol Biol Rev, (20030000), vol. 67, no. 4
    - CHALK et al., Nucleic Acids Res., (20050100), vol. 1, page 33
    - EVANS et al., IJP, (20170000), vol. 532
    - EVANS et al., Mol Pharm, (20170000), vol. 14
    - GUO et al., Mol Pharm, vol. 114, page 2017
    - GODHINO et al., IJP, (20140000), vol. 473
    - O'MAHONY et al., Pharm Res, (20130000), vol. 30
    - GOODING et al., EJPS, (20150000), vol. 71
    - MALHOTRA et al., "RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies", Molecular Biosystems, (20150000), pages 13 - 15
    - WEIHUA, T.; SIU-CHOON, N., Nature Protocol, (20080000), vol. 3, pages 691 - 695
    - GOODING M et al., European Journal of Pharmaceutical Sciences, (20150000), vol. 71, pages 80 - 92
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.